{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T17:37:07Z","timestamp":1793900227250,"version":"4.8.0"},"reference-count":52,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","license":[{"start":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T00:00:00Z","timestamp":1750377600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>The integration of chemotherapy, targeted therapy, and immunotherapy has emerged as the latest research focus for locally advanced gastric cancer (LAGC). This study aims to evaluate the efficacy and safety of various immunotherapy-based neoadjuvant regimens for LAGC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>PubMed, EmBase, and Cochrane Library databases were systematically searched based on the predefined inclusion criteria. Subsequently, the Stata software (version 17) was employed to separately integrate the outcome indicators of the single- and dual-arm studies, thereby systematically assessing the antitumor effects of three distinct immunotherapy-based regimens: neoadjuvant immunotherapy plus chemotherapy (NICT), neoadjuvant chemotherapy plus targeted therapy (NCTT), and NICT plus targeted therapy (NICTT).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>16 high-quality Phase II prospective single-arm clinical studies and 7 dual-arm clinical studies were selected. The pooled results from the single-arm studies indicated that immune-based neoadjuvant therapy could increase the rates of pathological complete response (pCR), severe treatment-related adverse events (TRAEs), 1- and 3-year disease-free survival (DFS), as well as 1- and 3-year overall survival (OS) to 20%, 30%, 91%, 74%, 94%, and 81%, respectively. Pairwise meta-analysis indicated that both the NICT and NICTT groups achieved higher rates of pCR, major pathological response (MPR), and complete resection (R0 resection) compared to the neoadjuvant chemotherapy (NCT) group, with the NICTT group exhibiting more pronounced effects. The NICTT group exhibited a significantly higher risk of experiencing severe TRAEs compared to the NCT group. ICIs\u00a0+\u00a0XELOX appeared to be a more appropriate NICT regimen, as it effectively enhanced the tumor response rate while inducing less severe TRAEs. Tumors exhibiting positive expression of PD-L1 or microsatellite instable (MSI) demonstrated a higher level of responsiveness to the NICT regimen.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Immunotherapy-based neoadjuvant regimens exhibit an enhanced potential for promoting tumor regression; however, caution is warranted due to the elevated risk of severe TRAEs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/js9.0000000000002815","type":"journal-article","created":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T14:00:13Z","timestamp":1750428013000},"page":"7222-7235","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":11,"title":["Efficacy and safety of immunotherapy-based neoadjuvant regimens in locally advanced gastric cancer: a meta-analysis based on high-quality clinical trials"],"prefix":"10.1097","volume":"111","author":[{"given":"Chen","family":"Liang","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, Beijing Jishuitan Hospital, Capital Medical University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyuan","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Beijing Friendship Hospital, Capital Medical University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Li","sequence":"additional","affiliation":[{"name":"School of Medicine, Nankai University, Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Beijing Jishuitan Hospital, Capital Medical University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyu","family":"Hou","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Beijing Jishuitan Hospital, Capital Medical University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junfu","family":"Zheng","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Beijing Jishuitan Hospital, Capital Medical University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weina","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Beijing Jishuitan Hospital, Capital Medical University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunzeng","family":"Jia","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Beijing Jishuitan Hospital, Capital Medical University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Beijing Jishuitan Hospital, Capital Medical University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengji","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Beijing Jishuitan Hospital, Capital Medical University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Beijing Jishuitan Hospital, Capital Medical University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,6,20]]},"reference":[{"key":"R1-20260109","first-page":"229\u201363","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"R2-20260109","doi-asserted-by":"crossref","first-page":"167\u201392","DOI":"10.6004\/jnccn.2022.0008","article-title":"Gastric cancer, version 2.2022, NCCN clinical practice guidelines in oncology","volume":"20","author":"Ajani","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"key":"R3-20260109","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s13045-023-01451-3","article-title":"Gastric cancer treatment: recent progress and future perspectives","volume":"16","author":"Guan","year":"2023","journal-title":"J Hematol Oncol"},{"key":"R4-20260109","doi-asserted-by":"crossref","first-page":"11\u201320","DOI":"10.1056\/NEJMoa055531","article-title":"Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer","volume":"355","author":"Cunningham","year":"2006","journal-title":"N Engl J Med"},{"key":"R5-20260109","first-page":"264\u201379","article-title":"Current treatment and recent progress in gastric cancer","volume":"71","author":"Joshi","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"R6-20260109","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41392-024-02097-4","article-title":"Digestive cancers: mechanisms, therapeutics and management","volume":"10","author":"Zhan","year":"2025","journal-title":"Signal Transduct Target Ther"},{"key":"R7-20260109","doi-asserted-by":"crossref","first-page":"27\u201340","DOI":"10.1016\/S0140-6736(21)00797-2","article-title":"First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial","volume":"398","author":"Janjigian","year":"2021","journal-title":"Lancet"},{"key":"R8-20260109","doi-asserted-by":"crossref","first-page":"2064\u201374","DOI":"10.1001\/jama.2023.19918","article-title":"Sintilimab plus chemotherapy for unresectable gastric or gastroesophageal junction cancer: the ORIENT-16 randomized clinical trial","volume":"330","author":"Xu","year":"2023","journal-title":"JAMA"},{"key":"R9-20260109","doi-asserted-by":"crossref","first-page":"e078876","DOI":"10.1136\/bmj-2023-078876","article-title":"Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial","volume":"385","author":"Qiu","year":"2024","journal-title":"BMJ"},{"key":"R10-20260109","first-page":"1415\u201326","article-title":"The safety and efficacy of neoadjuvant PD-1 inhibitor plus chemotherapy for patients with locally advanced gastric cancer: a systematic review and meta-analysis","volume":"111","author":"Yu","year":"2025","journal-title":"Int J Surg"},{"key":"R11-20260109","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s13045-024-01578-x","article-title":"Recent developments in immunotherapy for gastrointestinal tract cancers","volume":"17","author":"Chong","year":"2024","journal-title":"J Hematol Oncol"},{"key":"R12-20260109","doi-asserted-by":"crossref","first-page":"105906","DOI":"10.1016\/j.ijsu.2021.105906","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"88","author":"Page","year":"2021","journal-title":"Int J Surg"},{"key":"R13-20260109","doi-asserted-by":"crossref","first-page":"j4008","DOI":"10.1136\/bmj.j4008","article-title":"AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both","volume":"358","author":"Shea","year":"2017","journal-title":"BMJ"},{"key":"R14-20260109","first-page":"100082","article-title":"Transparency in the reporting of artificial INtelligence-the TITAN guideline","volume":"10","author":"Agha","year":"2025","journal-title":"Prem J Sci"},{"key":"R15-20260109","doi-asserted-by":"crossref","first-page":"712\u201316","DOI":"10.1046\/j.1445-2197.2003.02748.x","article-title":"Methodological index for non-randomized studies (minors): development and validation of a new instrument","volume":"73","author":"Slim","year":"2003","journal-title":"ANZ J Surg"},{"key":"R16-20260109","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The cochrane collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"R17-20260109","doi-asserted-by":"crossref","first-page":"652\u201361","DOI":"10.1007\/s10120-025-01606-w","article-title":"Neoadjuvant camrelizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastroesophageal junction adenocarcinoma: a single-arm, phase 2 trial, gastric cancer","volume":"28","author":"Ma","year":"2025","journal-title":"Gastric Cancer"},{"key":"R18-20260109","doi-asserted-by":"crossref","first-page":"S908","DOI":"10.1016\/j.annonc.2024.08.1533","article-title":"Efficacy and safety of disitamab vedotin (RC48) combined with camrelizumab and S-1 for neoadjuvant therapy of locally advanced gastric cancer with HER2 overexpression: preliminary results of a prospective, single-arm, phase II study","volume":"35","author":"Chai","year":"2024","journal-title":"Ann Oncol"},{"key":"R19-20260109","first-page":"2615\u201317","article-title":"Neoadjuvant sintilimab and apatinib combined with perioperative FLOT chemotherapy for locally advanced gastric cancer: a prospective, single-arm, phase II study","volume":"137","author":"Zhou","year":"2024","journal-title":"Chin Med J (Engl)"},{"key":"R20-20260109","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/s41467-022-35431-x","article-title":"Neoadjuvant therapy with immune checkpoint blockade, antiangiogenesis, and chemotherapy for locally advanced gastric cancer","volume":"14","author":"Li","year":"2023","journal-title":"Nat Commun"},{"key":"R21-20260109","doi-asserted-by":"crossref","first-page":"736\u201343","DOI":"10.1111\/cas.16425","article-title":"Phase II study of perioperative camrelizumab and XELOX for locally advanced gastric or gastroesophageal junction adenocarcinoma","volume":"116","author":"He","year":"2025","journal-title":"Cancer Sci"},{"key":"R22-20260109","doi-asserted-by":"crossref","first-page":"e010635","DOI":"10.1136\/jitc-2024-010635","article-title":"Phase 2 study of neoadjuvant durvalumab plus docetaxel, oxaliplatin, and S-1 with surgery and adjuvant durvalumab plus S-1 for resectable locally advanced gastric cancer","volume":"13","author":"Kang","year":"2025","journal-title":"J Immunother Cancer"},{"key":"R23-20260109","doi-asserted-by":"crossref","first-page":"100531","DOI":"10.1016\/j.medj.2024.10.008","article-title":"Neoadjuvant cadonilimab plus FLOT chemotherapy in locally advanced gastric\/gastroesophageal junction adenocarcinoma: a multicenter, phase 2 study","volume":"6","author":"Long","year":"2025","journal-title":"Med"},{"key":"R24-20260109","first-page":"2071\u201384","article-title":"Efficacy and safety of neoadjuvant sintilimab in combination with FLOT chemotherapy in patients with HER2-negative locally advanced gastric or gastroesophageal junction adenocarcinoma: an investigator-initiated, single-arm, open-label, phase II study","volume":"110","author":"Li","year":"2024","journal-title":"Int J Surg"},{"key":"R25-20260109","first-page":"8157\u201369","article-title":"Two-year outcomes and biomarker analysis of locally advanced gastric and gastroesophageal junction adenocarcinoma after neoadjuvant chemotherapy and immunotherapy from the phase II WuhanUHGI001 trial","volume":"31","author":"Sun","year":"2024","journal-title":"Ann Surg Oncol"},{"key":"R26-20260109","first-page":"519\u201330","article-title":"Neoadjuvant atezolizumab plus chemotherapy in gastric and gastroesophageal junction adenocarcinoma: the phase 2 PANDA trial","volume":"30","author":"Verschoor","year":"2024","journal-title":"Nat Med"},{"key":"R27-20260109","doi-asserted-by":"crossref","first-page":"e1674","DOI":"10.1002\/ctm2.1674","article-title":"Comprehensive multi-omics analysis of resectable locally advanced gastric cancer: assessing response to neoadjuvant camrelizumab and chemotherapy in a single-center, open-label, single-arm phase II trial","volume":"14","author":"Zhao","year":"2024","journal-title":"Clin Transl Med"},{"key":"R28-20260109","doi-asserted-by":"crossref","first-page":"e7006","DOI":"10.1002\/cam4.7006","article-title":"Efficacy and safety of camrelizumab combined with oxaliplatin and S-1 as neoadjuvant treatment in locally advanced gastric or gastroesophageal junction cancer: a phase II, single-arm study","volume":"13","author":"Zhong","year":"2024","journal-title":"Cancer Med"},{"key":"R29-20260109","doi-asserted-by":"crossref","first-page":"16090","DOI":"10.1200\/JCO.2023.41.16_suppl.e16090","article-title":"Toripalimab combined with fluorouracil, leucovorin calcium, oxaliplatin and irinotecan (FOLFIRINOX) regimen or combined with oxaliplatin and tegafur (SOX) regimen in perioperative treatment of locally advanced resectable gastric or gastroesophageal junction adenocarcinoma (G\/GEJ): an open-label, randomized, phase II study","volume":"41","author":"Liu","year":"2023","journal-title":"J Clin Oncol"},{"key":"R30-20260109","doi-asserted-by":"crossref","first-page":"1702\u201307","DOI":"10.1001\/jamaoncol.2023.4423","article-title":"Chemotherapy and immune checkpoint blockade for gastric and gastroesophageal junction adenocarcinoma","volume":"9","author":"Manji","year":"2023","journal-title":"JAMA Oncol"},{"key":"R31-20260109","doi-asserted-by":"crossref","first-page":"e003635","DOI":"10.1136\/jitc-2021-003635","article-title":"Efficacy and safety of neoadjuvant sintilimab, oxaliplatin and capecitabine in patients with locally advanced, resectable gastric or gastroesophageal junction adenocarcinoma: early results of a phase 2 study","volume":"10","author":"Jiang","year":"2022","journal-title":"J Immunother Cancer"},{"key":"R32-20260109","doi-asserted-by":"crossref","first-page":"927781","DOI":"10.3389\/fonc.2022.927781","article-title":"Efficacy and safety of sintilimab plus XELOX as a neoadjuvant regimen in patients with locally advanced gastric cancer: a single-arm, open-label, phase II trial","volume":"12","author":"Guo","year":"2022","journal-title":"Front Oncol"},{"key":"R33-20260109","doi-asserted-by":"crossref","first-page":"212\u201324","DOI":"10.1016\/S1470-2045(23)00541-7","article-title":"Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study","volume":"25","author":"Shitara","year":"2024","journal-title":"Lancet Oncol"},{"key":"R34-20260109","doi-asserted-by":"crossref","first-page":"410\u201320","DOI":"10.1200\/JCO.23.00975","article-title":"Perioperative atezolizumab plus fluorouracil, leucovorin, oxaliplatin, and docetaxel for resectable esophagogastric cancer: interim results from the randomized, multicenter, phase II\/III DANTE\/IKF-s633 trial","volume":"42","author":"Lorenzen","year":"2024","journal-title":"J Clin Oncol"},{"key":"R35-20260109","doi-asserted-by":"crossref","first-page":"S1106","DOI":"10.1016\/j.annonc.2022.07.1338","article-title":"Efficacy and safety of camrelizumab combined with FLOT versus FLOT alone as neoadjuvant therapy in patients with resectable locally advanced gastric and gastroesophageal junction adenocarcinoma who received D2 radical gastrectomy","volume":"33","author":"Min","year":"2022","journal-title":"Ann Oncol"},{"key":"R36-20260109","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/s41467-023-44309-5","article-title":"Neoadjuvant camrelizumab and apatinib combined with chemotherapy versus chemotherapy alone for locally advanced gastric cancer: a multicenter randomized phase 2 trial","volume":"15","author":"Lin","year":"2024","journal-title":"Nat Commun"},{"key":"R37-20260109","doi-asserted-by":"crossref","first-page":"S852","DOI":"10.1016\/j.annonc.2023.09.1425","article-title":"Perioperative camrelizumab (C) combined with rivoceranib (R) and chemotherapy (chemo) versus chemo for locally advanced resectable gastric or gastroesophageal junction (G\/GEJ) adenocarcinoma: the first interim analysis of a randomized, phase III trial (DRAGON IV","volume":"34","author":"Li","year":"2023","journal-title":"Ann Oncol"},{"key":"R38-20260109","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1200\/JCO.2024.42.3_suppl.312","article-title":"Atezolizumab and trastuzumab plus chemotherapy in patients with HER2+ locally advanced resectable gastric cancer or adenocarcinoma of the gastroesophageal junction: a multicenter, randomized, open-label phase II study","volume":"42","author":"Peng","year":"2024","journal-title":"J Clin Oncol"},{"key":"R39-20260109","doi-asserted-by":"crossref","first-page":"328\u201339","DOI":"10.5230\/jgc.2023.23.e17","article-title":"Neoadjuvant PD-1 inhibitor plus apatinib and chemotherapy versus apatinib plus chemotherapy in treating patients with locally advanced gastric cancer: a prospective, cohort study","volume":"23","author":"Wang","year":"2023","journal-title":"J Gastric Cancer"},{"key":"R40-20260109","first-page":"6477","article-title":"Neoadjuvant checkpoint blockade for cancer immunotherapy","volume":"367","author":"Topalian","year":"2020","journal-title":"Sci"},{"key":"R41-20260109","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s12943-021-01489-2","article-title":"Combination strategies with PD-1\/PD-L1 blockade: current advances and future directions","volume":"21","author":"Yi","year":"2022","journal-title":"Mol Cancer"},{"key":"R42-20260109","doi-asserted-by":"crossref","first-page":"e180013","DOI":"10.1001\/jamaoncol.2018.0013","article-title":"Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE-059 trial","volume":"4","author":"Fuchs","year":"2018","journal-title":"JAMA Oncol"},{"key":"R43-20260109","doi-asserted-by":"crossref","first-page":"234\u201347","DOI":"10.1016\/S1470-2045(21)00692-6","article-title":"Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial","volume":"23","author":"Kang","year":"2022","journal-title":"Lancet Oncol"},{"key":"R44-20260109","doi-asserted-by":"crossref","first-page":"1715\u201321","DOI":"10.1200\/JCO.2010.33.0597","article-title":"Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial","volume":"29","author":"Ychou","year":"2011","journal-title":"J Clin Oncol"},{"key":"R45-20260109","doi-asserted-by":"crossref","first-page":"5483\u201393","DOI":"10.1158\/0008-5472.CAN-12-2236","article-title":"Autophagy induced by conventional chemotherapy mediates tumor cell sensitivity to immunotherapy","volume":"72","author":"Ramakrishnan","year":"2012","journal-title":"Cancer Res"},{"key":"R46-20260109","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.3389\/fimmu.2020.01280","article-title":"Cancer stem cells-origins and biomarkers: perspectives for targeted personalized therapies","volume":"11","author":"Walcher","year":"2020","journal-title":"Front Immunol"},{"key":"R47-20260109","doi-asserted-by":"crossref","first-page":"169\u201378","DOI":"10.1016\/j.alit.2022.01.001","article-title":"Immune-related adverse events in various organs caused by immune checkpoint inhibitors","volume":"71","author":"Okiyama","year":"2022","journal-title":"Allergol Int"},{"key":"R48-20260109","first-page":"86\u2013104","article-title":"A review of cancer immunotherapy toxicity","volume":"70","author":"Kennedy","year":"2020","journal-title":"CA Cancer J Clin"},{"key":"R49-20260109","doi-asserted-by":"crossref","first-page":"765\u201379","DOI":"10.1007\/s10120-021-01182-9","article-title":"Human epidermal growth factor receptor 2 (HER2) in advanced gastric cancer: where do we stand?","volume":"24","author":"Roviello","year":"2021","journal-title":"Gastric Cancer"},{"key":"R50-20260109","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1186\/s12916-023-02841-7","article-title":"Safety and efficacy of apatinib in patients with advanced gastric or gastroesophageal junction adenocarcinoma after the failure of two or more lines of chemotherapy (AHEAD): a prospective, single-arm, multicenter, phase IV study","volume":"21","author":"Li","year":"2023","journal-title":"BMC Med"},{"key":"R51-20260109","first-page":"727\u201330","article-title":"The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer","volume":"600","author":"Janjigian","year":"2021","journal-title":"Nat"},{"key":"R52-20260109","doi-asserted-by":"crossref","first-page":"e2116240","DOI":"10.1001\/jamanetworkopen.2021.16240","article-title":"Effectiveness and safety of apatinib plus chemotherapy as neoadjuvant treatment for locally advanced gastric cancer: a nonrandomized controlled trial","volume":"4","author":"Lin","year":"2021","journal-title":"JAMA Network Open"}],"container-title":["International Journal of Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/JS9.0000000000002815","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T13:01:24Z","timestamp":1767963684000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/JS9.0000000000002815"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,20]]},"references-count":52,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/js9.0000000000002815","relation":{},"ISSN":["1743-9159"],"issn-type":[{"value":"1743-9159","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,20]]},"assertion":[{"value":"2025-04-15","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-07","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}